Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-07-01 | 317 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License $4750.00
- Team License (1-7 Users) $5250.00
- Site License $6500.00
- Corporate License $8750.00

Report description:

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Analysis

The Pharmaceutical contract development and manufacturing organization (CDMO) market size is valued at USD 258.88 billion in 2025 and is projected to reach USD 353.20 billion by 2030, reflecting a 6.41% CAGR. Robust outsourcing demand for complex biologics, the rise of high-potency APIs (HPAPIs), and artificial-intelligence-enabled-enabled process-development platforms underpin this trajectory. Peptide-based GLP-1 therapies, expanding vaccine programs, and sustained investment in digitally connected plants further amplify the need for specialist partners able to absorb capital and regulatory risks. North American innovators continue to anchor high-value biologics and gene-therapy work, while Asia-Pacific cost advantages accelerate capacity expansion. Consolidation-typified by Novo Holdings' USD 16.5 billion purchase of Catalent-signals a decisive shift toward end-to-end providers that combine development, scale-up, and commercial production.

Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Trends and Insights

Increasing Outsourcing Volume by Large Pharmaceutical Companies

Escalating R&D costs and pipeline complexity drive pharmaceutical majors to off-load non-core manufacturing. Asset-light models free capital for discovery while leveraging CDMO expertise to maintain global supply continuity. Lonza's USD 1.2 billion Vacaville site purchase from Roche underpins this transition, adding 330,000 L of biologics capacity to support blockbuster antibody demand. Outsourcing is most intense for sterile biologics and gene-editing therapies, where regulatory rigor and technical barriers

heighten the value of specialist partners.

Surge in Biologics and Complex-Molecule Pipelines

Biological entities now dominate new-drug filings, propelled by antibody-drug conjugates, mRNA vaccines, and cell-based therapeutics. Samsung Biologics secured USD 1.4 billion in new 2024 contracts and is expanding antibody-drug-conjugate suites, illustrating spiraling demand for cGMP biologics supply . Biologics' stringent cold-chain, contamination-control, and analytics requirements solidify a preference for full-scope CDMOs with proven regulatory track records.

Stringent Multi-Region Regulatory Requirements

Divergent dossiers and rolling updates such as the European Medicines Agency's new fee rules raise compliance budgets and prolong variation lead times EMA. CDMOs must operate duplicate quality-management systems and align data-integrity protocols across FDA, EMA, and PMDA audits, challenging smaller entrants.

Other drivers and restraints analyzed in the detailed report include:

Cost and Speed Advantage of Manufacturing in Emerging Markets / Consolidation Toward One-Stop CDMOs / High Capex for Sterile Biologics Suites /

For complete list of drivers and restraints, kindly check the Table Of Contents.

List of Companies Covered in this Report:

Thermo Fisher Scientific Inc. (Patheon) / Lonza Group / Catalent Inc. / Samsung Biologics Co. Ltd. / WuXi AppTec Inc. / Recipharm AB / Jubilant Pharmova Ltd. / Boehringer Ingelheim Group / Pfizer CentreOne / Aenova Holding GmbH / Fujifilm Diosynth Biotechnologies / Baxter BioPharma Solutions / Corden Pharma GmbH / AbbVie Contract Manufacturing / Cambrex Corporation / Syneos Health Inc. / IQVIA Holdings Inc. / Labcorp Drug Development / PAREXEL International Corporation / ICON PLC / Charles River Laboratories International Inc. / Eurofins Scientific SE / SGS Life Science Services SA / CMIC Holdings Co. Ltd / Novotech Pty Ltd / Hangzhou Tigermed Consulting Co. Ltd / Samsung Bioepis Co. Ltd / Tesa Labtec GmbH (TESA SE) / Tapemark / Famar SA /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /

Table of Contents:

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-07-01 | 317 pages | Mordor Intelligence

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$4750.00
	Team License (1-7 Users)	$5250.00
	Site License	$6500.00
	Corporate License	$8750.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-02-26
		Signature